Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T ...

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid

Related Keywords

Australia ,Japan ,United States ,South Korea ,New York ,Taiwan ,Pamela Keck ,Planegg Martinsried ,European Patent Office ,Prime Standard ,End To Technology ,End To Platform ,Business ,